Rapid and Deep Remission Induced by Blinatumomab for CD19-Positive Chronic Myeloid Leukemia in Lymphoid Blast Phase

JCO Precis Oncol. 2021 Jul 9:5:PO.21.00039. doi: 10.1200/PO.21.00039. eCollection 2021 Jul.

Authors

Shyam A Patel¹, Jacob R Bledsoe², Anne W Higgins², Lloyd Hutchinson², Jonathan M Gerber¹

Affiliations

¹ Department of Medicine-Hematology/Oncology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA.
² Department of Pathology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA.

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Bispecific* / therapeutic use
Blast Crisis / drug therapy
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy

Substances

Antibodies, Bispecific
blinatumomab